The "4th China Pharmaceutical Innovation and Investment Conference" grandly opened on September 21, 2019, at the Jinji Lake International Conference Center in Suzhou, Jiangsu Province, China. Guests from the four well - known global stock exchanges (Hong Kong, NASDAQ, London, and Shanghai Stock Exchanges) and top immunotherapy scientists gathered on the scene. They heatedly discussed the financing policies of globally leading financing platforms for pharmaceutical innovation enterprises, helped domestic biomedical enterprises find suitable cross - border financing channels, and promoted the improvement of the innovation and transformation capabilities of China's pharmaceutical industry.

On September 22, during the "Non - Listed Company Session" of the conference, Mr. Xie Gang, the secretary of the board of directors of Sichuan Jiuzhang Biotechnology Co., Ltd., gave a special roadshow titled "CHA for Injection - A Class 1 Natural Small - Molecule Tumor Immunotherapy Drug". He mainly reviewed the Phase I clinical research of CHA for injection and reported on the progress of the Phase II clinical research of CHA for injection in the treatment of glioma. Combining with the characteristics of Jiuzhang Biotech's projects, he summarized the investment highlights, attracting the enthusiastic attention of the guests and various investment companies at the venue.

The globally first - created anti - tumor Class 1 new drug independently developed by Jiuzhang Biotech - CHA for injection, is a natural small - molecule immune - metabolic anti - cancer drug with clear targets and a wide anti - cancer spectrum. Currently, a multi - center Phase II/III clinical study for the treatment of advanced malignant glioma is underway.